Less than one month ago, he stated Ariad was not looking for financing. Now this. I think all of the long term holders of Ariad will agree that the dilution is not a bad move at all, it's the double speak that annoys the shit out of us.
We are all happy with the progress of Ponatinib, but please explain your defense of Berger with regard to the double talk.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.